Clinical trials: High Cardiovascular Risk
Multiple Myeloma
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
The purpose of this study is to improve the clinical outcomes of research subjects with high-risk multiple myeloma in the context of the immediately preceding Total therapy 5 trial 2008-02 and Total therapy 3 trials 2003-33 and…
- Trial name
- NCT02128230
- Testing
- myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Dyslipidemia, Cardiovascular Diseases
Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events
High and Very High Risk cardiovascular patient journeys seems to vary from country to country, and current understanding of the process is incomplete.
- Conditions
- Dyslipidemia, Cardiovascular Diseases, Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
- Trial name
- SANTORINI (NCT04271280)
- Testing
- Non-interventional
- Where
- 540 sites in Austria, Belgium and 12 more
- Volunteers
- 9,559 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
High Risk Atherosclerotic Cardiovascular Disease
Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)
This study is designed to evaluate the efficacy of automated electronic alerts in the electronic health record to improve rates of best practices in the treatment of patients with hyperlipidemia who present in the setting of…
- Trial name
- NCT04394715
- Testing
- Electronic Alert
- Where
- 4 sites in United States
- Volunteers
- 2,596 people
- Sponsor
- Yale University
Hypercholesterolemia
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
This is a randomized, double-blind, double-dummy, active-controlled, parallel-group, multi-national, multi-center study to compare alirocumab (REGN727/SAR236553) versus ezetimibe in participants with primary hypercholesterolemia…
- Trial name
- NCT01709513
- Testing
- Atorvastatin, Ezetimibe, Alirocumab
- Where
- 70 sites in United States, Austria and 6 more
- Volunteers
- 314 people
- Sponsor
- Regeneron Pharmaceuticals
Hypertension, Cardiovascular Diseases
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks.
- Trial name
- NCT00904371
- Where
- 36 sites in Slovenia
- Volunteers
- 211 people
- Sponsor
- Boehringer Ingelheim
Myocardial Infarction
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
The core and extension studies assessed the safety and efficacy of aliskiren when added to optimized standard therapy in patients that have had a high risk acute myocardial infarction (heart attack).
- Trial name
- NCT00414609
- Testing
- Aliskiren
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 820 people
- Sponsor
- Novartis
Multiple Myeloma
Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
This research is being done to find out if altering the immune system by giving activated marrow infiltrating lymphocytes (MILs) can improve outcomes for multiple myeloma patients who receive a standard autologous stem cell…
- Trial name
- NCT01858558
- Testing
- aMIL, No aMIL
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hypercholesterolemia, Coronary Heart Disease
Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients
The purpose of this study is to evaluate the safety and efficacy of dosing with mipomersen for 26 weeks in patients with high cholesterol who are on a maximally tolerated dose of statin and who have a diagnosis that puts them at…
- Trial name
- NCT00770146
- Testing
- Mipomersen sodium
- Where
- 62 sites in United States
- Volunteers
- 158 people
- Sponsor
- Kastle Therapeutics, LLC
Non-Hodgkin's Lymphoma, Acute Leukemia in Remission
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
The purpose of this study is to find out if a combination of drugs (these are called: cyclophosphamide, sirolimus, and mycophenolate mofetil) will protect participants better against graft vs.
- Conditions
- Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis
- Trial name
- NCT03018223
- Testing
- Fludarabine, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Sub-optimal Vitamin D Status, Pre-diabetes
Effect of Vitamin D3 Supplementation on Insulin Resistance- The DIR Study
Insulin resistance is a state where the body does not respond as it should to the insulin it produces. Individuals who are insulin resistant are at increased risk of both heart disease and type 2 diabetes; importantly, diabetes…
- Conditions
- Sub-optimal Vitamin D Status, Pre-diabetes, Insulin Resistance
- Trial name
- NCT01889810
- Testing
- Vitamin D3 supplementation
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Intracranial Aneurysm, Brain Edema
Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients
This is a prospective, randomized controlled trial to determine if using FloTrac/EV1000 system in neurosurgical patients undergoing craniotomies for aneurysm repair or tumor resection complicated by cerebral edema, or complex…
- Conditions
- Intracranial Aneurysm, Brain Edema, Scoliosis, Surgery
- Trial name
- NCT02701582
- Testing
- Phenylephrine, Epinephrine, Albumin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- NYU Langone Health
Pulmonary Embolism, Deep Vein Thrombosis
Angel® Catheter Early Feasibility Clinical Study
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01847196
- Testing
- Angel® Catheter
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- BiO2 Medical
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or…
- Trial name
- DECLARE-TIMI58 (NCT01730534)
- Testing
- Dapagliflozin 10 mg
- Where
- 805 sites in United States, Argentina and 32 more
- Volunteers
- 17,190 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current…
- Trial name
- NCT02666664
- Testing
- ETC-1002
- Where
- 104 sites in United States, Canada and 4 more
- Volunteers
- 2,230 people
- Sponsor
- Esperion Therapeutics, Inc.
Myocardial Infarction, Coronary Revascularization
Transfusion Trigger After Operations in High Cardiac Risk Patients
The goal of the proposed study is to determine whether a liberal transfusion strategy (transfusion trigger at Hb < 10 gm/dl) in Veterans at high cardiac risk who undergo major open vascular and general surgery operations is…
- Conditions
- Myocardial Infarction, Coronary Revascularization, Acute Renal Failure
- Trial name
- TOP (NCT03229941)
- Testing
- Blood Transfusion
- Where
- 16 sites in United States
- Volunteers
- 1,424 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis
An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
This clinical study was designed to assess the efficacy, safety, and tolerability of long-term dosing of inclisiran and evolocumab given as subcutaneous injections in participants with high cardiovascular risk and elevated…
- Conditions
- Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
- Trial name
- ORION-3 (NCT03060577)
- Testing
- Inclisiran, Evolocumab
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Neutropenia, Sickle Cell Disease
Decitabine for High-Risk Sickle Cell Disease
Background: In sickle cell disease (SCD), the proteins in the red blood cells that carry oxygen do not behave normally. In parts of the body where there are low levels of oxygen or where oxygen is used more, the sickle hemoglobin…
- Trial name
- NCT01375608
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Stroke
A TargEted MAnageMent Intervention for Reducing Stroke Risk Factors in High Risk Ugandans
The proposed 2-phase project will first refine the TargetEd MAnageMent (TEAM) intervention to ensure acceptability across a broad range of Ugandans at risk for stroke and then test the effects of TEAM in reducing stroke risk in a…
- Trial name
- TEAM-U (NCT04685408)
- Testing
- TEAM, ETAU
- Where
- 3 sites in Uganda
- Volunteers
- 276 people
- Sponsor
- Case Western Reserve University
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
This phase II trial studies the effect of selinexor when combined with carfilzomib, daratumumab, and dexamethasone in treating patients with high-risk multiple myeloma that has come back (recurrent) or has not responded to…
- Trial name
- NCT04756401
- Testing
- Carfilzomib, Daratumumab, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Academic and Community Cancer Research United
Multiple Myeloma, Lymphocytic Leukemia, Chronic
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
The purpose of this study is to determine whether a reduced intensity conditioning regimen for stem cell transplant with donor cells will allow the donor cells to be effective without causing health problems.
- Conditions
- Multiple Myeloma, Lymphocytic Leukemia, Chronic, Lymphoma, Low-Grade
- Trial name
- NCT00143845
- Testing
- Reduced intensity conditioning, Rapid immunosuppressive taper, Prophylactic donor leukocyte infusions
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Michigan Rogel Cancer Center